Adagrasib for previously treated KRAS G12C mutated advanced non-small-cell lung cancer

Adagrasib is currently in clinical development for the treatment of KRAS G12C mutated advanced non-small-cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. Only a small subset of NSCLC patients carry the KRAS G12C mutation. When NSCLC spreads to other parts of the body, it is called advanced NSCLC. Treatment options vary depending on the cancer stage and mutations identified within the tumours. These options may include surgery, chemotherapy, radiotherapy, targeted drugs, and immunotherapy. However, patients with KRAS G12C mutated advanced NSCLC have limited treatments available, which highlights the need for further effective therapies for this subtype of advanced NSCLC.